研究業績
令和7年度（2025年度）
医学医療系業績
1. Sato T, To K, Sakurai F, Chihara K, Warabi E, Isobe T, Suzuki H, Shoda J, Okada K. Intestinal epithelial cell-specific restoration of Nrf2 gene in whole-body-knockout mice ameliorates acute colitis. Exp Anim. 2025, in press.
Intestinal epithelial cell-specific restoration of Nrf2 gene in whole-body-knockout mice ameliorates acute colitis - PubMed
2. Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, Yamamoto S, Matsubayashi M, Kobayashi T, Aoyama N, Saito D, Yokoyama K, Moriya K, Tsuchiya K, Shibui S, Kawamoto A, Shimizu H, Okamoto R, Sakamoto K, Yaguchi K, Kunisaki R, Akiyama S, Hayashi R, Hasui K, Kanmura S, Bamba S, Mishima Y, Kakimoto K, Sugimoto S, Nakazawa A, Abe T, Ogata H, Hisamatsu T. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study. J Gastroenterol. 2025 Jan 30.
First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study | Journal of Gastroenterology
3. Shintaro Akiyama, Ryohei Hayashi, Takeshi Takasago, Kurando Kusunoki, Hiroki Ikeuchi, Kento Takenaka, Kazuhiro Watanabe, Kazutaka Koganei, Nobuhiro Ueno, Mikihiro Fujiya, Naoki Hosoe, Fumikazu Koyama, Yasuhisa Sakata, Motohiro Esaki, Ken Takeuchi, Makoto Naganuma, Kiichiro Tsuchiya. Prevalence and Predictability of the Chicago Classification of Pouchitis in Ulcerative Colitis: A Multicenter Study in Japan,
Journal of Gastroenterology 2025
Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan | Journal of Gastroenterology
4. Toyoshima N, Mizuguchi Y, Takamaru H, Nakamura K, Kakugawa Y, Sakamoto T, Shiroyama M, Kawagoe R, Tsuchiya K, Shinmura K, Ikematsu H, Inaba A, Minakata N, Hotta K, Imai K, Takada K, Ito S, Misawa M, Wakamura K, Kudo SE, Tamai N, Sumiyama K, Ito M, Uraoka T, Tomaru S, Matsuda T, Fujimoto A, Shibata T, Saito Y：The Efficacy of Texture and Color Enhancement Imaging Observation in the Detection of Colorectal Lesions: A Multicenter, Randomized Controlled Trial (deTXIon Study).
Gastroenterology. 2025 Mar 18:S0016-5085(25)00524-4.doi: 10.1053/j.gastro.2025.03.007. Epub ahead of print. PMID: 40113100.
https://www.sciencedirect.com/science/article/pii/S0016508525005244
5. Shiraishi K, Okada M, Yamamoto S, Matsubara Y, Masuishi T, Shimozaki K, Yamamoto Y, Hirose S, Sugiyama K, Furuta M, Machida N, Takahashi N, Yoshii T, Kito Y, Tsuzuki T, Boku S, Tsuchihashi K, Sugaya A, Takayama T, Komori A, Mitani S, Matsumoto T, Nishimura T, Hirata K. The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma. Sci Rep. 2025 Mar 7;15(1):8031.
https://www.nature.com/articles/s41598-025-92657-7
6. Wakabayashi M, Masuishi T, Ogata T, Hanamura F, Furuta M, Yamamoto Y, Kawakami K, Hirano H, Kito Y, Izawa N, Takahashi N, Matsumoto T, Kawakami H, Ando T, Minashi K, Kudo C, Yoshimura K, Muro K. A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G. Future Oncol. 2025 Jun 6:1-7. doi: 10.1080/14796694.2025.2514935. Online ahead of print.
https://www.tandfonline.com/doi/full/10.1080/14796694.2025.2514935?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
7. Sato M, Yamamoto Y, Moriwaki T, Fukuda K, Tsuchiya K. Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells. Biochem Biophys Rep. 2025 Sep; 43 Online ahead of print.
https://www.sciencedirect.com/science/article/pii/S2405580825001608
